control groups

[키워드] 95% CI 95% confidence interval acute respiratory syndrome addressed Administered adverse event adverse events age all-cause mortality approach Arm Asymptomatic Asymptomatic disease baseline benefit Blood level blood levels calcifediol certainty certainty of evidence cholecalciferol clinical clinical status Cochrane COVID-19 Study Register comparability Consistency control group control groups coronavirus disease coronavirus diseases COVID-19 COVID-19 symptoms daily dose Data collection death decrease described determine died disease disease severity dose effective Effectiveness Effects Ethnicity event Evidence excluded Gender Health Organization heterogeneity High dose higher risk hospital discharge hypercalcaemia identify include indicate individual individuals inflammatory markers information Invasive mechanical ventilation investigated life maintain MERS methodological methodology Middle East Middle East respiratory syndrome Mild Mild disease moderate moderate or severe disease moderate to severe Mortality multiple dose multiple doses nine oral calcifediol oral cholecalciferol outcome outcomes participant Participants people with COVID-19 Placebo placebo group placebo treatment Population progression Quality Quality of life randomisation randomised controlled trial Randomised controlled trials RCT RCTs recording reported required risk of bia risk ratio Safe Safety searched Selection selective Serious Adverse Event Serious Adverse Events Severe acute respiratory syndrome severe disease Standard of care subject syndrome systematic review the placebo group the WHO treated Treatment treatment for COVID-19 treatment of COVID-19 viral clearance Vitamin D vitamin D serum Vitamin D status Vitamin D supplementation vomiting Web of Science WHO World Health Organization
[DOI] 10.1002/14651858.CD015043 PMC 바로가기 [Article Type] Article